ALK inhibitors have rapidly become the
standard of care for
ALK
+ NSCLC
1. Soda M, et al Nature 2007; 2. Ou, et al. Oncologist 2012; 3. Soda M, et al Proc Natl Acad Sci USA 2008
4. Bang, et al. ASCO 2010; 5. Kwak EL, et al N Engl J Med 2010; 6. Choi YL, et al. N Engl J Med 2010
2015
: Crizotinib
EU approval for
1L
ALK
+ NSCLC
2012
: Crizotinib EU
approval for 2L
ALK
+ NSCLC
2010
: First
crizotinib
resistance
mutations
reported
6
2008
: ALK-EML4
confirmed as
oncogenic driver in
NSCLC
3
2014
: US
approval of
ceritinib after
PD on
crizotinib
2011
:
Crizotinib US
approval for
ALK
+ NSCLC
2007
: first patient with
ALK
+ NSCLC treated
with crizotinib
2
2007
: ALK-EML4
identified in
NSCLC
2
2010
: First results
for crizotinib
published
4,5
2012
:
Crizotinib
included in
NCCN
guidelines
2015
:
Alectinib US
approval
after PD on
crizotinib
